Dataset Information

EUS-guided insertion of self-expandable metal stent and direct endoscopic necrosectomy in the management of infected walled-off pancreatic necrosis.

ABSTRACT:

SUBMITTER: Song M

PROVIDER: S-EPMC5989164 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

EUS-guided insertion of self-expandable metal stent and direct endoscopic necrosectomy in the management of infected walled-off pancreatic necrosis.

Song Mingjun M Ang Tiing Leong TL

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy 20160801 1

PMID: 29905217

Similar Datasets

Project description:BackgroundWith the increasing popularity of endoscopic ultrasound (EUS)-guided transmural interventions, walled-off necrosis (WON) of the pancreas is increasingly managed via non-surgical endoscopic interventions. However, there has been an ongoing debate over the appropriate treatment strategy following the initial EUS-guided drainage. Direct endoscopic necrosectomy (DEN) removes intracavity necrotic tissue, potentially facilitating early resolution of the WON, but may associate with a high rate of adverse events. Given the increasing safety of DEN, we hypothesised that immediate DEN following EUS-guided drainage of WON might shorten the time to WON resolution compared to the drainage-oriented step-up approach.MethodsThe WONDER-01 trial is a multicentre, open-label, superiority, randomised controlled trial, which will enrol WON patients aged ≥ 18 years requiring EUS-guided treatment in 23 centres in Japan. This trial plans to enrol 70 patients who will be randomised at a 1:1 ratio to receive either the immediate DEN or drainage-oriented step-up approach (35 patients per arm). In the immediate DEN group, DEN will be initiated during (or within 72 h of) the EUS-guided drainage session. In the step-up approach group, drainage-based step-up treatment with on-demand DEN will be considered after 72-96 h observation. The primary endpoint is time to clinical success, which is defined as a decrease in a WON size to ≤ 3 cm and an improvement of inflammatory markers (i.e. body temperature, white blood cell count, and C-reactive protein). Secondary endpoints include technical success, adverse events including mortality, and recurrence of the WON.DiscussionThe WONDER-01 trial will investigate the efficacy and safety of immediate DEN compared to the step-up approach for WON patients receiving EUS-guided treatment. The findings will help us to establish new treatment standards for patients with symptomatic WON.Trial registrationClinicalTrials.gov NCT05451901, registered on 11 July 2022. UMIN000048310, registered on 7 July 2022. jRCT1032220055, registered on 1 May 2022.

Dataset Information

EUS-guided insertion of self-expandable metal stent and direct endoscopic necrosectomy in the management of infected walled-off pancreatic necrosis.

Publications

EUS-guided insertion of self-expandable metal stent and direct endoscopic necrosectomy in the management of infected walled-off pancreatic necrosis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets